Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

O’Connor, Owen A.; Pro, Barbara; Pinter‐Brown, Lauren; Bartlett, Nancy L.; Popplewell, Leslie; Coiffier, Bertrand; Lechowicz, Mary Jo; Savage, Kerry J.; Shustov, Andrei R.; Gisselbrecht, Christian; Jacobsen, Eric; Zinzani, Pier Luigi; Furman, Richard R.; Goy, André; Haı̈oun, Corinne; Crump, Michael; Zain, Jasmine; Hsi, Eric D.; Boyd, Adam P.; Horwitz, Steven M.

doi:10.1200/jco.2010.29.9024

Cited by 549 publications

(411 citation statements)

References 20 publications

Supporting

Mentioning

383

Contrasting

Unclassified

Order By: Relevance

“…For patients failing primary therapy, a wide variety of new drugs are being studied. Pralatrexate [79] and romidepsin [80] have now been approved for use in the United States for relapsed/refractory PTCL. Other new agents, including lenalidomide [81], desatinib [82], and the aurora kinase inhibitor alisertib [83] all show some promise.…”

Section: Peripheral T-cell Lymphoma Not Otherwise Specifiedmentioning

confidence: 99%

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

Background: T‐cell lymphomas make up approximately 10%–15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.Diagnosis: The diagnosis of aggressive peripheral T‐cell lymphoma (PTCL) is usually made using the World Health Organization classification. The ability of hematopathologists to reproducibly diagnosis aggressive PTCL is lower than that for aggressive B‐cell lymphomas, with a range of 72%–97% for the aggressive PTCLs.Risk Stratification: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography scans seem to be useful as they are in aggressive B‐cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive PTCL is an important risk factor, with the best survival seen in anaplastic large‐cell lymphoma—particularly young patients with the anaplastic lymphoma kinase positive subtype.Risk‐Adapted Therapy: Anaplastic large‐cell lymphoma is the only subgroup to have a good response to a CHOP‐like regimen. Angioimmunoblastic T‐cell lymphoma has a prolonged disease‐free survival in only ∼20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL‐not otherwise specified is not one disease. Anthracycline‐containing regimens have disappointing results, and a new approach is needed. Natural killer/T‐cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy‐containing regimens. Enteropathy‐associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy, although selected patients with enteropathy‐associated PTCL seem to benefit from intensive therapy. Am. J. Hematol. 90:666–673, 2015. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Peripheral T-cell Lymphoma Not Otherwise Specifiedmentioning

confidence: 99%

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

show abstract

“…Pralatrexate, a novel antifolate with a high affinity for the reduced folate carrier (RFC-1) and novel mechanism of resistance when compared with methotrexate [357][358][359], was associated with an overall response rate of 29% in the PROPEL study, which was comprised largely of peripheral T-cell lymphoma patients, the majority of which had disease refractory to the most recent treatment [360]. Twelve patients with transformed MF were included in the study [361].…”

Section: Systemic Chemotherapymentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

“…The response rate in that trial was 54% for patients with T-cell lymphomas. Based on these encouraging data, the PROPEL trial was initiated [O'Connor et al 2011]. In this trial, 111 patients with relapsed or refractory PTCL were treated with pralatrexate weekly for 6 weeks on a 7-week cycle.…”

Section: Antifolatesmentioning

confidence: 99%

Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond

Foss

2011

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Abstract:The peripheral T-cell lymphomas are a rare, heterogeneous group of non-Hodgkin's lymphomas which have an aggressive clinical course. Treatment approaches have traditionally been similar to those of diffuse large B-cell lymphomas, but outcomes have been inferior. Novel approaches involving agents and pathways developed from a better understanding of the biology of the diseases have led to therapeutic advances. The introduction of new agents, including antifolates, immunoconjugates, histone deacetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling inhibitors have improved outcomes for patients with relapsed and refractory disease and are being incorporated into strategies for first-line therapy. Stem cell transplantation remains a potentially curative option for a subset of patients.

show abstract

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

Cited by 549 publications

References 20 publications

The aggressive peripheral T‐cell lymphomas: 2015

The aggressive peripheral T‐cell lymphomas: 2015

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond

Contact Info

Product

Resources

About